INTRODUCTION
The Joint United Nations Programme on HIV/ AIDS (UNAIDS) has set the goal of ending the AIDS world epidemic by 2030. In order to end this epidemic, they have established a 90-90-90 goal to be achieved by 2020 [1] . This goal includes 90% of individuals with HIV globally being diagnosed, on treatment, and virologically suppressed. It is estimated that by achieving all three targets, 73% of people living with HIV (PLWH) globally will become virologically suppressed [1] . No country has met that goal yet. Switzerland was the closest with 68% of its HIV population achieving virologic suppression, France 52%, and the US rates of virologic suppression were similar to sub-Saharan Africa at 30% versus 32%, respectively, and Russia had 9% of PLWH achieving virologic suppression [2] . Various approaches are necessary to achieve these goals, which include increasing HIV screening, providing universal access to treatment that is easily administered with minimal side effects and drug interactions, reducing virologic failure and resistance, minimizing costs, maintaining engagement and retention in care, advancing prevention practices, and eliminating the discrimination and stigma associated with HIV/AIDS.
HIV treatment is at the core of both preventing transmission and maintaining viral suppression as well as increasing life expectancy and reducing the risk of AIDS-defining cancers and non-AIDS defining cancers in HIV-positive patients [3, 4] . However, the number of PLWH on ART will not increase until they are appropriately diagnosed, linked to care, and retained in care. The World Health Organization (WHO) recommends initiation of ART in all individuals living with HIV/AIDS regardless of CD4 count; however, this is not currently the reality in all countries [5] . It is essential to make access to ART universal, affordable, uninterrupted, and lifelong. Studies have shown that ART initiation in HIV-positive patients has been shown to be 96% effective in reducing HIV transmission to HIV-negative partners, a concept known as ''treatment as prevention'' (TasP) [6] . The use of emtricitabine/tenofovir disoproxil fumarate by HIV-negative individuals as pre-exposure prophylaxis (PrEP) has been shown to be 92% effective in reducing the acquisition of HIV when strict adherence occurs and is taken on a daily basis [7] . Combining and advancing these approaches as well as ensuring that access is universal is key to achieving the UNAIDS goals.
Current ART availability is not universal, and, therefore, variations among HIV guidelines exist globally. The Department of Health and Human Services (DHHS) guidelines are very similar to the European AIDS Clinical Society (EACS) guidelines in regards to preferred treatment for treatment-naïve individuals [8, 9] . The DHHS-preferred regimens include several integrase transcriptase inhibitor (INSTI)-based regimens and one protease inhibitor (PI)-based regimen in combination with two nucleoside reverse transcriptase inhibitors (NRTIs; Table 1 ). The EACS recommend the same regimens included in the DHHS guideline with the addition of one non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (Table 1 ) [9] . The WHO guidelines, however, are quite different with limited treatment options including one NNRTI-based single tablet regimen (STR) or a dual NRTI backbone with either an NNRTI or INSTI as preferred therapy (Table 1 ) [10] .
Ensuring that all PLWH have access to new and more simplified regimens, regardless of nationality, is necessary to achieve global goals. [18] . Metformin should be limited to 1000 mg daily when co-administered with dolutegravir and adjusted if dolutegravir is discontinued [18] .
CURRENTLY AVAILABLE FORMULATIONS RECENTLY ADDED TO THE MARKET

Darunavir/Cobicistat and Atazanavir/ Cobicistat
Two new fixed-dose combination (FDC) products were released in the beginning of 2015 that contain a PI in combination with the pharmacokinetic booster cobicistat. These products include atazanavir 300 mg/cobicistat 150 mg (Evotaz with additional ARV agents [20, 21] . The DHHS guidelines list both of these combination products as alternative regimen options for treatment-naïve patients given in addition to two NRTIs [8] . These new combinations reduce the pill burden associated with administering either atazanavir or darunavir individually with ritonavir.
Cobicistat boosts by the same mechanism as ritonavir ( Table 3 ). Cobicistat inhibits renal tubular secretion and therefore can increase SCr without causing actual renal tubular damage [20, 21] . Drug-drug interactions with cobicistat were similar to ritonavir, yet medications metabolized through CYP1A2, CYP2C8, CYP2C9, and CYP2C19 are expected to interact with ritonavir but remain unaltered by cobicistat.
A randomized double-blinded study was performed comparing the efficacy and safety of once-daily atazanavir 300 mg/cobicistat 150 mg to atazanavir 300 mg ? ritonavir 100 mg both given in combination with emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg [22] . Subjects in the study were randomly assigned to either group resulting in 344 in the cobicistat group and 348 in the ritonavir group. Virologic suppression for the cobicistat-containing combination was non-inferior to the ritonavir-containing regimen. At week 48, 85.2% of those in the cobicistat group had an HIV RNA load of \50 copies/ml compared to 87.4% in the ritonavir group (95% CI: -7.4% to 3%). Overall the side effect profile of atazanavir 300 mg boosted by cobicistat versus ritonavir was very similar. Hyperbilirubinemia, jaundice, and scleral icterus were the most common adverse effects leading to discontinuation (n = 25 in both groups). Smaller increases in total cholesterol and triglyceride levels in the respectively, P = 0.03 for both) compared to efavirenz 400 mg (39%; 13%, respectively).
Therefore, lower doses of efavirenz may be used to achieve virologic suppression but should be used with caution in medications that induce efavirenz metabolism. The WHO has adopted efavirenz 400 mg ? emtricitabine (or lamivudine) ? tenofovir disoproxil fumarate as an alternative option for the initiation of ART.
Tenofovir Alafenamide
One of the major developments in HIV therapy was the release of co-formulated products containing tenofovir alafenamide (elvitegravir (Table 5) . A discussion of the HIV pipeline for the treatment of HIV-1 in adults is discussed below.
Phase III
Fostemsavir
Fostemsavir belongs to a new class of ARVs known as AIs [44] . It is the oral prodrug of temsavir, which exerts its action by directly binding to HIV-1 glycoprotein (gp)120 and causing a conformational change that prevents viral attachment to the CD4 receptor [45] . In 2015, fostemsavir was granted breakthrough designation by the US FDA, accelerating its development and review [46] . Because of its unique mechanism, fostemsavir is likely to offer an additional option for patients who have developed extensive resistance to other classes of ARVs.
In the ongoing phase III trial of treatment-experienced patients with resistance, intolerability, and/or contraindications to at least three classes of ARVs, patients will be assigned to either a randomized or non-randomized cohort based on the number [47] . Patients able to receive either one or two currently approved ARVs will be assigned to the randomized cohort, and patients without any activity to remaining ARVs will be assigned to the non-randomized cohort. Patients in the randomized cohort will receive either placebo or fostemsavir 600 mg orally twice daily for days 1-8. Beginning on day 9, they will receive fostemsavir 600 mg orally twice daily plus an optimized background regimen (OBR). Patients in the non-randomized cohort will receive fostemsavir 600 mg orally twice daily plus OBR beginning on day 1. Patients will be followed for C48 weeks, and results are expected in 2018.
Ibalizumab
Ibalizumab is another AI currently in phase III trials [48, 49] . It is an intravenously administered monoclonal antibody that exerts its mechanism by binding to the extracellular domain II of the CD4 receptor, causing a post-conformational change that prevents viral fusion and entry to the CD4 cell [50] . The results of an early clinical trial demonstrated a reduction in HIV-1 RNA levels of 1.33 log 10 in patients that received a single-dose 10 mg/kg IV infusion of ibalizumab on day 14 post-infusion.
In the US, ibalizumab is available to patients who qualify for compassionate use [49] . Similar to fostemsavir, ibalizumab is likely to be reserved for heavily treatment-experienced patients who have developed extensive resistance to other ARV classes. The safety and efficacy of ibalizumab is currently being evaluated in a phase III trial of HIV-infected, treatment-experienced adults with extensive resistance [48] . Enrolled participants will be monitored on days 0-6 on 
Doravirine
Doravirine is an NNRTI in phase III studies [51] . Doravirine has been shown to maintain in vitro activity against the common NNRTI resistance mutations K103N, Y181C, G190A, E101K, E138K, and K103N/Y181C [52] . Doravirine has been shown to select for the following distinct mutations in vitro: V106A, F227L, and L234I.
Because of its unique resistance profile, there is believed to be limited cross-resistance between doravirine and the other NNRTIs. Compared to the other NNRTIs, doravirine does not inhibit or induce CYP450 enzymes, may be taken without regard to food, and is administered once daily [53] . [55] . Drug-related AEs at week 48 were reported in 31.5% and 56.5% of patients in the doravirine-and efavirenz-containing groups, respectively. Both groups had similar rates of discontinuation secondary to drug-related AEs up to week 24 (doravirine 2.8%; efavirenz 5.5%). The most common AEs reported were CNS-related, being dizziness (doravirine 6.5%; efavirenz 25.9%), insomnia (doravirine 6.5%; efavirenz 2.8%), abnormal dreams (doravirine 5.6%; efavirenz 14.8%), and nightmares (doravirine 5.6%; efavirenz 8.3%) [55] .
Depression (doravirine 0.9%; efavirenz 1.9%) and suicide (doravirine 0.0%; efavirenz 0.9%)
were rare in both groups [55] . Doravirine is being evaluated as a FDC tablet (doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg) administered once daily compared to efavirenz/ emtricitabine/tenofovir disoproxil fumarate or PI-boosted regimens (atazanavir, darunavir, lopinavir) ? 2 NRTI backbone [56, 57].
Once-Daily Raltegravir
Raltegravir is an INSTI that is currently available as a twice-daily dosed ARV and part of a preferred first-line regimen in ARV-naive HIV-1 patients [58] . In an effort to simplify raltegravir-based therapy, a once-daily dosing option is currently in development [59, 60] . A once-daily dosing strategy was previously evaluated in the QDMRK trial [61] . In this non-inferiority trial, once-daily raltegravir 800 mg was compared to the approved dosing regimen of raltegravir 400 mg twice daily.
However, the trial failed to demonstrate non-inferiority, and once-daily raltegravir 800 mg was not approved. Currently, raltegravir is being investigated as a once-daily dose of 1200 mg (given as two 600 mg tablets) compared to the standard twice-daily dosing in treatment-naïve patients [60] . Initial findings demonstrated that raltegravir 1200 mg once daily was non-inferior to raltegravir 400 mg twice daily, each with emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, as assessed by the proportion of patients with HIV-1 RNA viral load \40 copies/ml at week 48 [62] . Approval of this dosing regimen could potentially offer another preferred first-line regimen, dosed once-daily with minimal drug-drug interactions, for treatment-naïve HIV-1 patients.
Bictegravir (GS-9883)/Emtricitabine/Tenofovir Alafenamide
Bictegravir is a second-generation INSTI that does not require pharmacokinetic boosting, unlike elvitegravir, but is being evaluated in combination with emtricitabine/tenofovir alafenamide compared to dolutegravir/ lamivudine/abacavir or dolutegravir ? emtricitabine/tenofovir alafenamide in HIV-1 ARV-naive adults [63, 64] . Since bictegravir has entered phase 3, data from the phase 2 study are likely to be promising in regards to safety and efficacy [65] . Phase I
GS-9620
Investigational compound GS-9620 is being evaluated as part of the HIV eradication strategy [77] . The ultimate goal of GS-9620, a Toll-like receptor (TLR) 7 agonist, is to stimulate latent HIV out of viral reservoirs in HIV-infected cells and enhance a virus-specific immune response in those with HIV [77] . Preclinical data in macaque monkeys with simian immunodeficiency virus (SIV) treated with multiple doses of a TLR agonist led to immune activation in two macaque monkeys and SIV RNA blips as well as decreased SIV DNA [78] .
Based on these data, a phase 1b safety study in HIV-positive humans taking ART is underway.
Although 
